Photo: Davidi Vardi / Pikiwiki Israel
A venture fund linked to Schneider Children’s Medical Center and Clalit has raised about $20 million in an initial closing and is targeting roughly $50 million in total, according to a report published Wednesday. Schneider Children’s VC has already invested in three companies, with individual investments ranging from $500,000 to $3 million, the report said.
For companies building medical tools for children, this offers a route to funding and clinical testing. For parents, it is not the announcement of an approved treatment or a promise that a new product will help their child.
The distinction between money raised and money sought matters. The fund has not announced that it has raised the full $50 million target. The report describes an initial pool of around $20 million that has allowed investment activity to begin.
A fund built around children’s health
SCVC operates as a separate entity from Schneider, although the hospital and Clalit are partners, according to the report. Its anchor investors include Schneider and Clalit, the Dor Group and managing partner Ronen Gadot.
Operations began in February after an agreement with Clalit, Gadot said in the report. The November 4 report therefore does not mean the fund first opened for business Wednesday. He said it had assessed about 170 companies before selecting three for investment.
Schneider Children’s VC says its strategy puts children’s health first: invest in companies addressing children’s health needs, evaluate technology in clinical workflows, then help companies develop their products and reach the market.
That is a business model as well as a medical ambition. Investors hope that identifying useful technology early and testing it with clinicians will reduce development risk. Such a model does not remove the need to prove safety, performance and value.
Clinical access comes with safeguards
SCVC says its partnership can provide access to clinical expertise at Schneider and longitudinal health data through Clalit. Its website explicitly says all data use is subject to regulatory and ethics approvals, data governance and privacy safeguards.
That qualification is important. A partnership with a hospital does not give a startup unrestricted access to patient records, and an investment decision is not the same as a regulatory decision allowing a product to be used in care.
The fund’s website identifies Cellergy Therapeutics and Noumena AI among the businesses in its ecosystem. It describes Cellergy’s first-in-human work at Schneider as expected in 2027, rather than already completed. That timeline is a development expectation, not evidence of a proven treatment result.
The gap the fund wants to address
SCVC says on its website that children receive only a small fraction of medical innovation. It invests in companies addressing children’s health needs, sometimes with a path into larger adult markets.
For founders, the test will be whether capital, clinical feedback and a route into healthcare systems help turn an idea into a product that meets a real need. For hospitals and families, the test remains evidence: what the technology does, how well it works and whether its benefits outweigh its risks.
JBizNews Desk | New York
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
